We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Annual Meeting Offers Industry Education and Entertainment

By LabMedica International staff writers
Posted on 08 Jun 2017
Image: Genome editing with CRISPR-Cas9 offers the potential to treat human genetic disease (Photo courtesy of Feng Zhang).
Image: Genome editing with CRISPR-Cas9 offers the potential to treat human genetic disease (Photo courtesy of Feng Zhang).
Registration has opened for the 2017 annual meeting of the American Association of Clinical Chemistry, which has promised novel and interesting sessions that will highlight emerging science, practices, and technologies across the spectrum of clinical laboratory medicine.

The 69th AACC Annual Scientific Meeting & Clinical Lab Expo will be held in San Diego, CA, USA, from July 30 to August 3. In addition to a strong lineup of plenary speakers, which will be headed by Dr. Jennifer Doudna, professor of chemistry and molecular and cell biology at the University of California, Berkeley (USA) – who will be speaking about advances in CRISPR/Cas9 gene editing technology – there will be a mock courtroom session and two quiz games.

The mock trial session will illustrate the importance of expert witness testimony in resolving litigation associated with toxicology and clinical laboratories. One quiz game will pit the AACC leadership against members of the Society for Young Clinical Laboratorians. The teams will contest various laboratory medicine topics such as oncology and cardiovascular biomarkers, molecular testing, point-of-care testing, therapeutic drug management/toxicology, and over-utilized or outdated tests.

The second quiz game will engage the audience on topics addressing Zika virus, mass spectrometry, antimicrobial resistance, and other infectious disease issues and diagnostic solutions.

A highlight of the conference will be the Qualcomm Tricorder XPRIZE special session. Two participants in this $10 million global competition to develop devices capable of diagnosing at least 13 health conditions and continuously monitoring five vital signs, all with a consumer-friendly interface and weighing no more than five pounds (2.27 kilograms), will present their innovations.

Related Links:
AACC Annual Scientific Meeting & Clinical Lab Expo
University of California, Berkeley

New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Online QC Software
Acusera 24•7
Prefilled Tubes
Prefilled 5.0ml Tubes
Hematology Consumables
Bioblood Devices

Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Molecular Diagnostics

view channel
Image

Blood Test Could Help Fast-Track Lymphoma Diagnosis in Resource-Limited Settings

Lymphoma can be difficult to distinguish from infections and benign conditions, while definitive diagnosis often depends on surgical tissue sampling and specialized pathology that may not be readily available.... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more